Overview

Phase II Study of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd